APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting ESAs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting ESAs Industry Growth and Trends Forecast to 2032

28 December 2025104 pages

Choose your research edition.

Industry ResearchLong-acting ESAs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting ESAs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Long-acting ESAs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting ESAs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting ESAs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting ESAs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting ESAs include Amgen, Cipla, CKD Pharma, Dr. Reddy's Laboratories, Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Torrent Pharmaceuticals and Hansoh Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting ESAs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting ESAs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting ESAs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting ESAs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-acting ESAs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting ESAs Market by Company

Amgen

Cipla

CKD Pharma

Dr. Reddy's Laboratories

Kissei Pharmaceutical

Kyowa Hakko Kirin

Sanwa Kagaku Kenkyusho

Torrent Pharmaceuticals

Hansoh Pharma

Roche

Kyowa Kirin

Long-acting ESAs Segment by Type

Pegmolesatide

Methoxy Polyethylene Glycol-Epoetin Beta

Darbepoetin Alfa

Long-acting ESAs Segment by Application

Renal Anemia

Cancer

Other

Long-acting ESAs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting ESAs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting ESAs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting ESAs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting ESAs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-acting ESAs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pegmolesatide Table 2. Major Company of Methoxy Polyethylene Glycol-Epoetin Beta Table 3. Major Company of Darbepoetin Alfa Table 4. Global Long-acting ESAs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 6. Global Long-acting ESAs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Long-acting ESAs Sales Market Share in Value by Type (2021-2026) Table 9. Global Long-acting ESAs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 11. Global Long-acting ESAs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Long-acting ESAs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Long-acting ESAs Sales Market Share in Value by Type (2027-2032) Table 14. Global Long-acting ESAs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 16. North America Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 18. Europe Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 22. Latin America Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Long-acting ESAs Sales by Type (2021-2026) & (US$ Million) Table 25. Long-acting ESAs Industry Trends Table 26. Long-acting ESAs Industry Drivers Table 27. Long-acting ESAs Industry Opportunities and Challenges Table 28. Long-acting ESAs Industry Restraints Table 29. Global Long-acting ESAs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Long-acting ESAs Revenue Market Share by Company (2021-2026) Table 31. Global Long-acting ESAs Sales by Company (2021-2026) & (K Units) Table 32. Global Long-acting ESAs Sales Share by Company (2021-2026) Table 33. Global Long-acting ESAs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Long-acting ESAs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Long-acting ESAs Major Company Production Sites and Headquarters Table 36. Global Long-acting ESAs Company, Product Type & Application Table 37. Global Long-acting ESAs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Long-acting ESAs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Long-acting ESAs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Long-acting ESAs Sales by Region (2021-2026) & (K Units) Table 42. Global Long-acting ESAs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Long-acting ESAs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Long-acting ESAs Sales Market Share in Value by Region (2021-2026) Table 45. Global Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Long-acting ESAs Sales by Region (2027-2032) & (K Units) Table 47. Global Long-acting ESAs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Long-acting ESAs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Long-acting ESAs Sales Market Share in Value by Region (2027-2032) Table 50. Global Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Long-acting ESAs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 53. Global Long-acting ESAs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Long-acting ESAs Sales Market Share in Value by Application (2021-2026) Table 56. Global Long-acting ESAs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 58. Global Long-acting ESAs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Long-acting ESAs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Long-acting ESAs Sales Market Share in Value by Application (2027-2032) Table 61. Global Long-acting ESAs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 63. North America Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 65. Europe Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 69. Latin America Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Long-acting ESAs Sales by Application (2021-2026) & (US$ Million) Table 72. Amgen Company Information Table 73. Amgen Business Overview Table 74. Amgen Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Amgen Long-acting ESAs Product Portfolio Table 76. Amgen Recent Development Table 77. Cipla Company Information Table 78. Cipla Business Overview Table 79. Cipla Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Cipla Long-acting ESAs Product Portfolio Table 81. Cipla Recent Development Table 82. CKD Pharma Company Information Table 83. CKD Pharma Business Overview Table 84. CKD Pharma Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. CKD Pharma Long-acting ESAs Product Portfolio Table 86. CKD Pharma Recent Development Table 87. Dr. Reddy's Laboratories Company Information Table 88. Dr. Reddy's Laboratories Business Overview Table 89. Dr. Reddy's Laboratories Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio Table 91. Dr. Reddy's Laboratories Recent Development Table 92. Kissei Pharmaceutical Company Information Table 93. Kissei Pharmaceutical Business Overview Table 94. Kissei Pharmaceutical Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Kissei Pharmaceutical Long-acting ESAs Product Portfolio Table 96. Kissei Pharmaceutical Recent Development Table 97. Kyowa Hakko Kirin Company Information Table 98. Kyowa Hakko Kirin Business Overview Table 99. Kyowa Hakko Kirin Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Kyowa Hakko Kirin Long-acting ESAs Product Portfolio Table 101. Kyowa Hakko Kirin Recent Development Table 102. Sanwa Kagaku Kenkyusho Company Information Table 103. Sanwa Kagaku Kenkyusho Business Overview Table 104. Sanwa Kagaku Kenkyusho Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio Table 106. Sanwa Kagaku Kenkyusho Recent Development Table 107. Torrent Pharmaceuticals Company Information Table 108. Torrent Pharmaceuticals Business Overview Table 109. Torrent Pharmaceuticals Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Torrent Pharmaceuticals Long-acting ESAs Product Portfolio Table 111. Torrent Pharmaceuticals Recent Development Table 112. Hansoh Pharma Company Information Table 113. Hansoh Pharma Business Overview Table 114. Hansoh Pharma Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Hansoh Pharma Long-acting ESAs Product Portfolio Table 116. Hansoh Pharma Recent Development Table 117. Roche Company Information Table 118. Roche Business Overview Table 119. Roche Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Roche Long-acting ESAs Product Portfolio Table 121. Roche Recent Development Table 122. Kyowa Kirin Company Information Table 123. Kyowa Kirin Business Overview Table 124. Kyowa Kirin Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Kyowa Kirin Long-acting ESAs Product Portfolio Table 126. Kyowa Kirin Recent Development Table 127. North America Long-acting ESAs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. North America Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 129. North America Long-acting ESAs Sales Market Share by Country (2021-2026) Table 130. North America Long-acting ESAs Sales Forecast by Country (2027-2032) & (K Units) Table 131. North America Long-acting ESAs Sales Market Share Forecast by Country (2027-2032) Table 132. North America Long-acting ESAs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America Long-acting ESAs Market Size by Country (2021-2026) & (US$ Million) Table 134. North America Long-acting ESAs Market Share by Country (2021-2026) Table 135. North America Long-acting ESAs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America Long-acting ESAs Market Share Forecast by Country (2027-2032) Table 137. Europe Long-acting ESAs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Europe Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 139. Europe Long-acting ESAs Sales Market Share by Country (2021-2026) Table 140. Europe Long-acting ESAs Sales Forecast by Country (2027-2032) & (K Units) Table 141. Europe Long-acting ESAs Sales Market Share Forecast by Country (2027-2032) Table 142. Europe Long-acting ESAs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe Long-acting ESAs Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe Long-acting ESAs Market Share by Country (2021-2026) Table 145. Europe Long-acting ESAs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe Long-acting ESAs Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Long-acting ESAs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 149. Asia-Pacific Long-acting ESAs Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific Long-acting ESAs Sales Forecast by Country (2027-2032) & (K Units) Table 151. Asia-Pacific Long-acting ESAs Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Long-acting ESAs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Long-acting ESAs Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific Long-acting ESAs Market Share by Country (2021-2026) Table 155. Asia-Pacific Long-acting ESAs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific Long-acting ESAs Market Share Forecast by Country (2027-2032) Table 157. Latin America Long-acting ESAs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Latin America Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 159. Latin America Long-acting ESAs Sales Market Share by Country (2021-2026) Table 160. Latin America Long-acting ESAs Sales Forecast by Country (2027-2032) & (K Units) Table 161. Latin America Long-acting ESAs Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America Long-acting ESAs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America Long-acting ESAs Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America Long-acting ESAs Market Share by Country (2021-2026) Table 165. Latin America Long-acting ESAs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America Long-acting ESAs Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Long-acting ESAs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa Long-acting ESAs Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa Long-acting ESAs Sales Forecast by Country (2027-2032) & (K Units) Table 171. Middle East and Africa Long-acting ESAs Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Long-acting ESAs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Long-acting ESAs Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa Long-acting ESAs Market Share by Country (2021-2026) Table 175. Middle East and Africa Long-acting ESAs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa Long-acting ESAs Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Long-acting ESAs Distributors List Table 180. Long-acting ESAs Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Long-acting ESAs Image Figure 2. Global Long-acting ESAs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting ESAs Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting ESAs Sales (2021-2032) & (K Units) Figure 5. Pegmolesatide Image Figure 6. Global Pegmolesatide Sales YoY Growth (2021-2032) & (K Units) Figure 7. Methoxy Polyethylene Glycol-Epoetin Beta Image Figure 8. Global Methoxy Polyethylene Glycol-Epoetin Beta Sales YoY Growth (2021-2032) & (K Units) Figure 9. Darbepoetin Alfa Image Figure 10. Global Darbepoetin Alfa Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Long-acting ESAs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Long-acting ESAs Market Share by Type 2025 VS 2032 Figure 13. North America Long-acting ESAs Sales Market Share in Volume by Type in 2025 Figure 14. North America Long-acting ESAs Sales Market Share in Value by Type in 2025 Figure 15. Europe Long-acting ESAs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Long-acting ESAs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Long-acting ESAs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Long-acting ESAs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Long-acting ESAs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Long-acting ESAs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Long-acting ESAs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Long-acting ESAs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Long-acting ESAs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Renal Anemia Image Figure 26. Global Renal Anemia Sales YoY Growth (2021-2032) & (K Units) Figure 27. Cancer Image Figure 28. Global Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Long-acting ESAs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Long-acting ESAs Market Share by Application 2025 VS 2032 Figure 33. North America Long-acting ESAs Sales Market Share in Volume by Application in 2025 Figure 34. North America Long-acting ESAs Sales Market Share in Value by Application in 2025 Figure 35. Europe Long-acting ESAs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Long-acting ESAs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Long-acting ESAs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Long-acting ESAs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Long-acting ESAs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Long-acting ESAs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Long-acting ESAs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Long-acting ESAs Sales Market Share in Value by Application in 2025 Figure 43. North America Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Long-acting ESAs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Long-acting ESAs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Long-acting ESAs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Long-acting ESAs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Long-acting ESAs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Long-acting ESAs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Long-acting ESAs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Long-acting ESAs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Long-acting ESAs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Long-acting ESAs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Long-acting ESAs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Long-acting ESAs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Long-acting ESAs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Pegmolesatide
  • Methoxy Polyethylene Glycol-Epoetin Beta
  • Darbepoetin Alfa
Applications
  • Renal Anemia
  • Cancer
  • Other
Companies covered
  • Amgen
  • Cipla
  • CKD Pharma
  • Dr. Reddy's Laboratories
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Sanwa Kagaku Kenkyusho
  • Torrent Pharmaceuticals
  • Hansoh Pharma
  • Roche
  • Kyowa Kirin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting ESAs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-acting ESAs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-acting ESAs Market by Type
  6. 1.3.1 Pegmolesatide
  7. 1.3.2 Methoxy Polyethylene Glycol-Epoetin Beta
  8. 1.3.3 Darbepoetin Alfa
  9. 1.4 Global Long-acting ESAs Market Size by Type
  10. 1.4.1 Global Long-acting ESAs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Long-acting ESAs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Long-acting ESAs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Long-acting ESAs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Long-acting ESAs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Long-acting ESAs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Long-acting ESAs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Long-acting ESAs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-acting ESAs Industry Trends
  2. 2.2 Long-acting ESAs Industry Drivers
  3. 2.3 Long-acting ESAs Industry Opportunities and Challenges
  4. 2.4 Long-acting ESAs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-acting ESAs Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-acting ESAs Sales (2021-2026)
  3. 3.3 Global Top Players by Long-acting ESAs Price (2021-2026)
  4. 3.4 Global Long-acting ESAs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting ESAs Major Company Production Sites & Headquarters
  6. 3.6 Global Long-acting ESAs Company, Product Type & Application
  7. 3.7 Global Long-acting ESAs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting ESAs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting ESAs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting ESAs Tier 1, Tier 2, and Tier 3
4 Long-acting ESAs Regional Status and Outlook
  1. 4.1 Global Long-acting ESAs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-acting ESAs Historic Market Size by Region
  3. 4.2.1 Global Long-acting ESAs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-acting ESAs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-acting ESAs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-acting ESAs Forecasted Market Size by Region
  7. 4.3.1 Global Long-acting ESAs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-acting ESAs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-acting ESAs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-acting ESAs by Application
  1. 5.1 Long-acting ESAs Market by Application
  2. 5.1.1 Renal Anemia
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Long-acting ESAs Market Size by Application
  6. 5.2.1 Global Long-acting ESAs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Long-acting ESAs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Long-acting ESAs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Long-acting ESAs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Long-acting ESAs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Long-acting ESAs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Long-acting ESAs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Long-acting ESAs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Amgen
  2. 6.1.1 Amgen Company Information
  3. 6.1.2 Amgen Business Overview
  4. 6.1.3 Amgen Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Amgen Long-acting ESAs Product Portfolio
  6. 6.1.5 Amgen Recent Developments
  7. 6.2 Cipla
  8. 6.2.1 Cipla Company Information
  9. 6.2.2 Cipla Business Overview
  10. 6.2.3 Cipla Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Cipla Long-acting ESAs Product Portfolio
  12. 6.2.5 Cipla Recent Developments
  13. 6.3 CKD Pharma
  14. 6.3.1 CKD Pharma Company Information
  15. 6.3.2 CKD Pharma Business Overview
  16. 6.3.3 CKD Pharma Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 CKD Pharma Long-acting ESAs Product Portfolio
  18. 6.3.5 CKD Pharma Recent Developments
  19. 6.4 Dr. Reddy's Laboratories
  20. 6.4.1 Dr. Reddy's Laboratories Company Information
  21. 6.4.2 Dr. Reddy's Laboratories Business Overview
  22. 6.4.3 Dr. Reddy's Laboratories Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio
  24. 6.4.5 Dr. Reddy's Laboratories Recent Developments
  25. 6.5 Kissei Pharmaceutical
  26. 6.5.1 Kissei Pharmaceutical Company Information
  27. 6.5.2 Kissei Pharmaceutical Business Overview
  28. 6.5.3 Kissei Pharmaceutical Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Kissei Pharmaceutical Long-acting ESAs Product Portfolio
  30. 6.5.5 Kissei Pharmaceutical Recent Developments
  31. 6.6 Kyowa Hakko Kirin
  32. 6.6.1 Kyowa Hakko Kirin Company Information
  33. 6.6.2 Kyowa Hakko Kirin Business Overview
  34. 6.6.3 Kyowa Hakko Kirin Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kyowa Hakko Kirin Long-acting ESAs Product Portfolio
  36. 6.6.5 Kyowa Hakko Kirin Recent Developments
  37. 6.7 Sanwa Kagaku Kenkyusho
  38. 6.7.1 Sanwa Kagaku Kenkyusho Company Information
  39. 6.7.2 Sanwa Kagaku Kenkyusho Business Overview
  40. 6.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio
  42. 6.7.5 Sanwa Kagaku Kenkyusho Recent Developments
  43. 6.8 Torrent Pharmaceuticals
  44. 6.8.1 Torrent Pharmaceuticals Company Information
  45. 6.8.2 Torrent Pharmaceuticals Business Overview
  46. 6.8.3 Torrent Pharmaceuticals Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Torrent Pharmaceuticals Long-acting ESAs Product Portfolio
  48. 6.8.5 Torrent Pharmaceuticals Recent Developments
  49. 6.9 Hansoh Pharma
  50. 6.9.1 Hansoh Pharma Company Information
  51. 6.9.2 Hansoh Pharma Business Overview
  52. 6.9.3 Hansoh Pharma Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hansoh Pharma Long-acting ESAs Product Portfolio
  54. 6.9.5 Hansoh Pharma Recent Developments
  55. 6.10 Roche
  56. 6.10.1 Roche Company Information
  57. 6.10.2 Roche Business Overview
  58. 6.10.3 Roche Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Roche Long-acting ESAs Product Portfolio
  60. 6.10.5 Roche Recent Developments
  61. 6.11 Kyowa Kirin
  62. 6.11.1 Kyowa Kirin Company Information
  63. 6.11.2 Kyowa Kirin Business Overview
  64. 6.11.3 Kyowa Kirin Long-acting ESAs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Kyowa Kirin Long-acting ESAs Product Portfolio
  66. 6.11.5 Kyowa Kirin Recent Developments
7 North America by Country
  1. 7.1 North America Long-acting ESAs Sales by Country
  2. 7.1.1 North America Long-acting ESAs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-acting ESAs Sales by Country (2021-2026)
  4. 7.1.3 North America Long-acting ESAs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-acting ESAs Market Size by Country
  6. 7.2.1 North America Long-acting ESAs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-acting ESAs Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-acting ESAs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-acting ESAs Sales by Country
  2. 8.1.1 Europe Long-acting ESAs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-acting ESAs Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-acting ESAs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-acting ESAs Market Size by Country
  6. 8.2.1 Europe Long-acting ESAs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-acting ESAs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-acting ESAs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-acting ESAs Sales by Country
  2. 9.1.1 Asia-Pacific Long-acting ESAs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-acting ESAs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-acting ESAs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-acting ESAs Market Size by Country
  6. 9.2.1 Asia-Pacific Long-acting ESAs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-acting ESAs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-acting ESAs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-acting ESAs Sales by Country
  2. 10.1.1 South America Long-acting ESAs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-acting ESAs Sales by Country (2021-2026)
  4. 10.1.3 South America Long-acting ESAs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-acting ESAs Market Size by Country
  6. 10.2.1 South America Long-acting ESAs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-acting ESAs Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-acting ESAs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-acting ESAs Sales by Country
  2. 11.1.1 Middle East and Africa Long-acting ESAs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-acting ESAs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-acting ESAs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-acting ESAs Market Size by Country
  6. 11.2.1 Middle East and Africa Long-acting ESAs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-acting ESAs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-acting ESAs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-acting ESAs Value Chain Analysis
  2. 12.1.1 Long-acting ESAs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-acting ESAs Production Mode & Process
  7. 12.2 Long-acting ESAs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-acting ESAs Distributors
  10. 12.2.3 Long-acting ESAs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst